trial

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)

NCTId NCT05136690
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 38 (actual)
Sponsored by Merck Sharp & Dohme LLC
Primary completion 2022-09-23
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
38 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2022-04-27
Primary completion
2022-09-23
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Nicotine patchMK-4334

Sponsors

Merck Sharp & Dohme LLCLead Sponsor

Sites

2 total
Long Beach, United StatesMarlton, United States

Facts & assertions

4 sourced
Enrollment
38
Phase
PHASE1
Primary Completion Date
2022-09-23
Status
COMPLETED
relationships
The graph out of here
drug
Nicotine patch
drug
MK-4334
drug
lead_sponsor
Merck Sharp & Dohme LLC
company
indication
Cognitive Impairment Associated With Schizophrenia
indication